Long-term outcome after allogeneic stem cell transplantation in multiple myeloma

Sini Luoma*, Raija Silvennoinen, Auvo Rauhala, Riitta Niittyvuopio, Eeva Martelin, Vesa Lindström, Jouni Heiskanen, Liisa Volin, Tapani Ruutu, Anne Nihtinen

*Corresponding author for this work

Research output: Contribution to journalArticleScientificpeer-review

6 Citations (Scopus)


The role of allogeneic hematopoietic stem cell transplantation (allo-SCT) in multiple myeloma is controversial. We analyzed the results of 205 patients transplanted in one center during 2000–2017. Transplantation was performed on 75 patients without a previous autologous SCT (upfront-allo), on 74 as tandem transplant (auto-allo), and on 56 patients after relapse. Median overall survival (OS) was 9.9 years for upfront-allo, 11.2 years for auto-allo, and 3.9 years for the relapse group (p = 0.015). Progression-free survival (PFS) was 2.4, 2.4, and 0.9 years, respectively (p < 0.001). Non-relapse mortality at 5 years was 8% overall, with no significant difference between the groups. Post-relapse survival was 4.1 years for upfront-allo and auto-allo, and 2.6 years for the relapse group (p = 0.066). Survival of high-risk patients was reduced. In multivariate analysis, the auto-allo group had improved OS and chronic graft-versus-host disease was advantageous in terms of PFS, OS, and relapse incidence. Late relapses occurred in all groups. Allo-SCT resulted in long-term survival in a small subgroup of patients. Our results indicate that auto-allo-SCT is feasible and could be considered for younger patients in the upfront setting.

Original languageEnglish
Pages (from-to)1553-1567
Number of pages15
JournalAnnals of Hematology
Issue number6
Publication statusPublished - Jun 2021
MoE publication typeA1 Journal article-refereed


Dive into the research topics of 'Long-term outcome after allogeneic stem cell transplantation in multiple myeloma'. Together they form a unique fingerprint.

Cite this